Heart rate score, a measure related to chronotropic incompetence in pacemaker patients

Arjun D. Sharma, MD,* Mark Richards, MD, PhD, FHRS,† Brian Olshansky, MD, FHRS,‡ Nicholas Wold, MS,§ Paul Jones, MS,§ David Perschbacher, BS,¶ Bruce L. Wilkoff, MD, FHRS

From the *Medical Devices Consultants LLC, St Paul, Minnesota, †NWOCC, Toledo, Ohio, §University of Iowa Hospital and Clinics, Iowa City, Iowa, ‡Boston Scientific, St. Paul, Minnesota, and ¶Cleveland Clinic, Cleveland, Ohio.

BACKGROUND Heart rate score (HrSc) ≥70% in cardiac resynchronization therapy defibrillator and implantable cardioverter-defibrillator subjects predicts 5-year mortality risk. A high HrSc suggests few sensed cardiac cycles above the programmed lower rate.

OBJECTIVE To determine if HrSc is related to chronotropic incompetence (CI) in pacemaker (PM) subjects.

METHODS HrSc is the percentage of all atrial-paced and sensed events in the single tallest 10 beats/min histogram bin programmed to DDD 60/min. The prospective LIFE study of PM subjects examined multiple treadmill-based measures of CI. The 1-month postimplant DDD 60/min PM rate histogram prior to treadmill was retrospectively analyzed for HrSc. Measures of CI were applied to submaximal treadmill data in the DDD mode. HrSc was compared to these CI measures and to clinical indications for PM.

RESULTS The 1-month histogram demonstrated HrSc ≥70% in 43% of subjects. HrSc ≥70% correlated with a clinical diagnosis of sick sinus syndrome (P < .001). CI was present in 34%–88% of subjects by treadmill-based measures. Agreement between treadmill-based measures for CI was poor and varied from 39% to 83%. HrSc ≥70%, as a measure of CI, was most highly correlated with unpaced heart rate <70% of age-predicted maximum heart rate (67%) (odds ratio 3.7, P < .001).

CONCLUSIONS HrSc ≥70% correlates with treadmill measures of CI and clinical sick sinus syndrome. HrSc ≥70% is a measure of CI in PM subjects that is inexpensive, repeatable, and quantitative.

KEYWORDS Chronotropic incompetence; Heart rate score; Pacemaker; Risk assessment; Treadmill testing

(Heart Rhythm O2 2021;2:124–131) © 2021 Heart Rhythm Society. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Heart rate score (HrSc) is a recently described machine learning–derived parameter of long-term heart rate variation. It is defined as the percentage of all atrial-paced and sensed events in the single tallest 10 beats/min device histogram bin.1 Subjects receiving an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) with an earliest postimplant HrSc ≥70% were at greatest risk of all-cause mortality over the next 5 years.1,2 Dual sensor–based pacing lowered HrSc by a greater amount than single-sensor rate-responsive pacing,3 with an associated increase in pacing rate. The underlying mechanisms contributing to the prognostic value of HrSc are unknown, but chronotropic incompetence (CI) is one proposed mechanism suggested by the relationship of HrSc to rate-responsive pacing, and the HrSc parameter being defined by the rate histogram.

We hypothesized that HrSc may correlate with CI in pacemaker (PM) subjects. The “Limiting chronotropic incompetence in pacemaker recipients” (LIFE) study is one of only a few prior studies that compared multiple treadmill-based measures of CI.4 The deidentified data from the LIFE study was reassessed first to determine the relationship between HrSc and the clinical indication for PM implantation, and secondly to assess the relationship of an abnormal HrSc ≥70% to treadmill-based measures of CI.

Methods

This study is a retrospective analysis of deidentified data from the LIFE clinical study published in 2008 and owned by Boston Scientific (Marlboro, MA). The LIFE study enrolled 1566 subjects after informed consent. The trial met requirements of the Declaration of Helsinki (2000). The research was carried out prior to 2008 at a time when there was no requirement for trial registration. All subjects met clinical indications for an implantable PM and underwent implantation of an Insignia Plus or Ultra dual-chamber PM (Boston Scientific, Marlboro, MA). Two of the indications listed in the LIFE study, sick sinus syndrome and sinus bradycardia, were grouped together as sick sinus syndrome for most of this analysis, as they both pertain to
CI. At 1 month postimplant, subjects were to undergo submaximal exercise treadmill testing in the DDD-60 mode to assess the spontaneous rhythm that could indicate chronotropic incompetence. The 4 measures of CI based on treadmill testing in the LIFE study were based on heart rate reserve (HRR), age-predicted maximum heart rate (APMHR), and metabolic chronotropic reserve (MCR) slope:

1. \(<80\% \text{ HRR} = \frac{\text{Max HR} - \text{Rest HR}}{\text{Max HR}}\)
2. \(<85\% \text{ APMHR} = \frac{\text{Max HR} - 0.85 \times \text{APMHR}}{\text{Max HR}}\)
3. \(<70\% \text{ APMHR} = \frac{\text{Max HR} - 0.7 \times \text{APMHR}}{\text{Max HR}}\)
4. \(\text{MCR slope (LIFE definition)} = \frac{\text{slope of HRR to metabolic reserve}}{\text{spontaneous rhythm}}\) at each stage (MCR slope \(<0.8\) determined by the Wilkoff method, and a setting for no statistically significant differences in demographics between these 3 groups to suggest selective sampling.)
Correlation of heart rate score with clinical diagnosis

The demographics for LIFE study subjects with HrSc available are shown in Table 1 (n = 501), and are grouped by HrSc (low <30%, medium 30%–69%, high ≥70% as in prior publications). Low HrSc subjects (HrSc <30%) tended to be younger. The indication for all pacemakers listed by the LIFE investigators was sinus node disease (sick sinus syndrome and sinus bradycardia) in 58% and atrioventricular conduction disease in 25%, with the remainder having both diagnoses. Subjects with HrSc ≥70% (n = 214) more likely had a clinical diagnosis of sick sinus syndrome (76.2%) than subjects with HrSc <30% or mid-range HrSc 30%–69% (P < .001). Subjects with HrSc ≥70% were less likely to have atrioventricular conduction disorders (14%) (Table 1). This is consistent with subjects with high HrSc having less spontaneous heart rates above the LRL of 60/min.

Baseline heart rate score compared to 4 treadmill-based measures of chronotropic incompetence

The rates of CI for each of the 4 treadmill-based measures and HrSc ≥70% are shown in Figure 3A. CI rates across the 5 measures ranged from 34% (LIFE-MCR slope <0.8) to 88% (<80% HRR). Agreement of chronotropic response classification, including both CC and CI, between each pairwise comparison of the measures is shown in Figure 3B. Conventional measures of CI (<80% HRR, peak HR <85% APMHR, peak HR <70% APMHR, and LIFE definition of CI) have a wide range of agreement with each other (39%–83% agreement in CI and CC classifications) (Figure 2B). HrSc ≥70% as a measure of CI correlated with age-predicted maximum heart rate CI measures (peak heart rate <70% APMHR and <85% APMHR; P < .001 for both) (Table 2). The <80% HRR (P = .3) and MCR slope <0.8 (P = .5) were not individually correlated with HrSc ≥70% as measures of CI (Table 2 and Figure 3B). A repeated measures logistic regression model utilizing all available CI classifications indicated that those considered to have CI by any of the CI treadmill measures were collectively more likely to have an HrSc ≥70% (odds ratio: 2.0, 95% confidence interval: 1.5–2.6, P < .001; Table 2).

The distributions of baseline HrSc for the subsequent 4 treadmill-based CI measures are shown in Figure 4 for patients deemed to have CI by that measure in blue and CC in red. Across all 4 treadmill-based measures of CI, subjects
otherwise defined as having CI had higher HrSc (Figure 4). In contrast, those subjects classified as CC had a broad distribution of HrSc and 3 of the 4 measures of CI had a small peak at HrSc 30%–39% among CC subjects. This is consistent with spontaneous sinus rhythm above the LRL of 60. The strongest association between CI and HrSc/C2170% was observed with the CI definition of peak treadmill heart rate, 70% of APMHR (odds ratio 3.7, P < .001; Table 2). This association can be seen in Figure 4C, in which the CI patients were more likely to have HrSc/C2170% and the CC patients more likely to have HrSc <70%. A weaker, but still significant, association was observed between HrSc/C2170% and CI defined by peak treadmill heart rate <85% of APMHR (Table 2 and Figure 4B).

**Discussion**

Pacemaker and defibrillator subjects who have little or no spontaneous heart rates above the programmed LRL, as seen on the device histogram, have a high HrSc >70%.

**Table 1** LIFE study subjects with heart rate score data available (n = 501); baseline demographic data presented for each group, with statistical differences by analysis of variance

| Variable                        | Statistic | HrSc Group       | P value |
|---------------------------------|-----------|------------------|---------|
|                                 |           | <30% (n = 39)    | 30%–69% (n = 248) | ≥70% (n = 214) |
| Age                             | Mean ± SD | 64 ± 13          | 72 ± 11  | 73 ± 10  | <.001 |
| Sex                             | Female (%)| 28.2%            | 41.9%    | 39.3%    | .26   |
| BMI                             | Mean ± SD | 28.6 ± 6.6       | 27.9 ± 6.0 | 28.0 ± 5.0 | .76   |
| BP systolic                     | Mean ± SD | 134 ± 22         | 140 ± 23 | 143 ± 25 | .09   |
| BP diastolic                    | Mean ± SD | 73 ± 13          | 72 ± 13  | 71 ± 13  | .41   |
| NYHA HF functional class        | Class I (%)| 41.0%            | 37.1%    | 40.2%    | .12   |
|                                 | Class II (%)| 0.0%             | 6.9%     | 10.3%    |       |
|                                 | Class III (%)| 2.6%             | 0.4%     | 0.5%     |       |
|                                 | Class IV (%)| 7.7%             | 9.3%     | 12.6%    |       |
|                                 | None (%)    | 48.7%            | 46.4%    | 36.5%    |       |
| Indication for pacemaker implant| Sick sinus syndrome (%) | 30.8% | 32.3% | 46.3% | <.001 |
|                                 | Sinus bradycardia (%) | 10.3% | 13.7% | 29.9% |       |
|                                 | Third-degree AV block (%) | 28.2% | 20.6% | 7.9% |       |
|                                 | Second-degree AV block (%) | 15.4% | 17.7% | 6.1% |       |

*BMI = body mass index; BP = blood pressure; HF = heart failure; HrSc = heart rate score.*
This led us to hypothesize that there is a relationship between HrSc and CI. The major observations of this analysis using the LIFE trial data are, first, that HrSc ≥70% is associated with the clinical diagnosis of sick sinus syndrome (P < .001) and thus, CI (Table 1); second, that HrSc ≥70% is associated with previously described treadmill-based definitions of CI, such as maximum heart rate on a standardized exercise test <70% of APMHR (P < .001) (Table 2); and furthermore, that any treadmill-based measure of CI is associated with HrSc ≥70%, supporting our hypothesis that HrSc ≥70% is a marker of CI.

The connection between HrSc and the maximum heart rate on a treadmill test may not be immediately clear. The long-term rate histogram does not provide beat-to-beat heart rate variation in the plots and the HrSc does not reflect the peak heart rate on the treadmill test, as HrSc was measured before treadmill. HrSc does reflect the heart rate distribution during activities of daily living in the prior 30 days. The tallest rate histogram bin is almost always the lowest rate bin above the LRL of the pacemaker, 60 in this study (Figure 1). The HrSc is measured by the height of the tallest rate bin, which is usually not the highest rate bin, which is where the peak treadmill heart rate would be registered. However, there is a mathematical connection between the APMHR and the HrSc. The lower the APMHR, the less spontaneous variation in heart rate will occur above the LRL of 60/min with activities of daily living. Less heart rate increases will result in most of the heart beats being concentrated into fewer bins, resulting in a higher percentage of beats in the lowest bin (higher HrSc). Thus, there is an inverse relationship between APMHR and HrSc, with low APMHR associated with higher HrSc.

CI indicates an ineffective acceleration in heart rate to meet physiological demands. It refers to an impaired sinus chronotropic competence; HRR = heart rate reserve.8 CI may involve failure to achieve a certain percentage of age-predicted maximum heart rate in response to exercise.9,10 A sinus rate slower than expected during a portion of exercise,11 and an abnormally slow rate of heart rate recovery post exercise.12 CI can be associated with resting sinus bradycardia.13,14 Despite lack of a standard definition for identifying subjects with CI, CI has been associated with increased all-cause mortality15 and cardiovascular mortality in multiple studies,16,17 including the Framingham longitudinal follow-up.18

An association between CI and HF was recently reviewed.19 CI is a heterogeneous phenotypic diagnosis with multiple associated etiologic causes, such as HF and pharmacologic therapy.8,13 As there are multiple methods of assessment and detection of CI, the incidence, prevalence, and even definitions of CI vary widely. In a PM population the LIFE study definition yielded a CI prevalence of 34%.6 In contrast, in a chronic HF population, CI was observed in 66% of subjects, as defined by <80% of the HRR (% HRR).20 The LIFE study demonstrated a strong association between CI and mortality in the long-term follow-up.18

### Table 2 Association of heart rate score ≥70% and various definitions of chronotropic incompetence

| Definition of CI | OR   | 95% CI | P    |
|-----------------|------|--------|------|
| <80% HRR        | 1.3  | 0.8–2.4 | .307 |
| <85% APMHR      | 2.2  | 1.4–3.4 | <.001|
| <70% APMHR      | 3.7  | 2.5–5.5 | <.001|
| LIFE definition of CI | 1.3  | 0.7–2.4 | .455 |
| All definitions† | 2.0  | 1.5–2.6 | <.001|

APMHR = age-predicted maximum heart rate; CI = chronotropic incompetence; HRR = heart rate reserve; OR = odds ratio; 95% CI = 95% confidence interval.

Odds ratio >1 indicates HrSc ≥70% associated with CI. Separate logistic regression models were evaluated for each definition of CI.

†Accounted for repeated measures within patient.

---

**Figure 3** A: Percentage of subjects in LIFE study meeting definitions for chronotropic incompetence (CI). B: Comparison of CI and chronotropic competence (CC) classifications between all pairwise combinations of definitions. Accuracy defined as all classifications that agreed across both measures (CC or CI) divided by all classifications. P value < .05 indicates significant concordance between measures. Heart rate score >70% correlates with <70% age-predicted maximum heart rate (APMHR) and <85% APMHR. HR = heart rate; HRR = heart rate reserve.
study did not document objective evidence of systolic and diastolic dysfunction, biomarker data, or HF etiology, and there was no HF drug control, and thus no conclusions regarding the association of CI and HF can be made based on this analysis.

Measures of CI described previously include a reduced MCR slope,\(^\text{17}\) achieving \(70\%–85\%\) of APMHR on submaximal exercise testing,\(^\text{6}\) or reduction in age-predicted HRR.\(^\text{21}\) MCR slope, APMHR, and HRR require careful exercise testing. This is costly, is difficult to perform in subjects with physical limitations, and reflects variability of patient performance at one point in time. In addition, none of these treadmill-based measures has emerged as the clear gold standard for CI management. HrSc\(^/-/C21\) can be measured repeatedly and remotely from a PM interrogation, is low cost, is quantitative, and is an alternative measure of CI that correlates with APMHR and a clinical diagnosis of sick sinus syndrome. Future prospective validation is required to determine the utility of HrSc as a diagnostic tool for CI. It also needs to be determined if HrSc measurement can be extended to wearable monitors.

Prior studies using a large database of ICD and CRT-D subjects have shown that an early postimplant HrSc \(\geq 70\%\) predicts higher mortality in subjects over a 5-year follow-up.\(^\text{1}\) Furthermore, CRT-D subjects with baseline HrSc \(\geq 70\%\) programmed to DDDR (vs DDD) in a propensity score–matched population have a better survival.\(^\text{2}\) CI may also be associated with cardiovascular mortality.\(^\text{16–18}\) Accordingly, HrSc may be suitable for future investigations of the relationships between CI and survival in other device populations.

We have recently demonstrated that HrSc can be improved (reduced) and peak exercise rate increased by programming rate response with minute ventilation combined with accelerometer.\(^\text{3}\) A strategy of reducing HrSc and thus improving HrSc with sensor-driven programming could be tested prospectively and randomized in future outcomes trials. Rate-responsive pacing has shown to increase exercise times compared to fixed-rate pacing.\(^\text{22}\) However, simply programming faster pacing rates with more aggressive sensor response and higher maximal sensor rates may not be the best approach in all PM subjects. There is evidence that with pacing at faster rates there can be reductions in

---

*Figure 4* Baseline heart rate score (HrSc) profiles in DDD pacing mode for subjects in LIFE study with chronotropic competence (CC; in red) and chronotropic incompetence (CI; in blue) based on the subsequent 4 definitions of CI. A: <80% heart rate reserve definition of CI. CC and CI have similar distributions of HrSc. B: <85% age-predicted maximum heart rate (APMHR) definition of CI. CC and CI have different distributions of HrSc. C: <70% APMHR definition of CI. CC and CI have the greatest divergence of HrSc distribution. Subjects with CI have a distribution skewed towards high HrSc \(\geq 70\%\) compared to subjects with CC most evident for <70% APMHR. D: Metabolic chronotropic reserve slope (LIFE) definition of CI. CC and CI have similar distributions of HrSc.
myocardial performance in some subjects. More recently, the myocardial force frequency relationship to pacing rate has been examined noninvasively in subjects with left ventricular systolic dysfunction. Tailoring the maximal sensor rate to the critical rate, increased exercise time, and increased peak oxygen consumption but above a critical paced rate (mean 109 ppm, <70% APMHR) contractility was reduced. Thus, there is evidence that in the HF population with CI, care needs to be taken to not pace overly rapidly.

**Limitations**
This study is retrospective and hypothesis-generating. Therefore, there is a need to assess HrSc prospectively to identify PM subjects with CI and test for prospective outcomes. This study did not set out to examine which definition of CI is best. It is unclear what endpoints would be used and likely would require some long-term outcome measure to determine a “gold-standard test for CI.” However, this is not central to use of HrSc. The sensitivity and specificity of HrSc for identifying CI are not defined owing to lack of a gold standard. In this study, HrSc was measured by a PM and, therefore, conclusions about CI apply to that population. Lastly, this study was done entirely with the PM LRL of 60 ppm.

**Conclusion**
These are the first to suggest that HrSc is associated with CI in a PM population. HrSc is also associated with the clinical diagnosis of sinus node dysfunction. HrSc correlates best with the established treadmill-based measure of CI exercise rate <70% APMHR. HrSc ≥70% is common (43%) in the LIFE study PM population. This HrSc methodology can be used in most devices that have fixed bin widths on the rate histograms; and unlike other measures of CI, it does not require an exercise test, which adds cost and is affected by patient comorbidities. Correlation of HrSc with clinical and exercise test indicators of CI suggests that HrSc has the potential to become a measure for CI, to optimize rate-responsive pacing in PM subjects, and to remotely monitor worsening HF.

**Funding Sources**
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Disclosures**
The authors disclose the following: Arjun D. Sharma – consultant VivaQuant, Autonomix, DyaMx, stock Medicoil, BSX; Mark Richards – consultant speaker for Janssen, consultant Acutus, consultant and investigator Boston Scientific, consultant and speaker Abbott, shareholder Cardialen, consultant Cardionomics; Brian Olshansky – chair DSMB REDUCE-IT trial Amarin, consultant Respicardia, consultant speaker Lundbeck, consultant Sanofi Aventis; Nick Wold, Paul Jones, and David Perschbacher – are employees of Boston Scientific and receive salary; Bruce L. Wilkoff – consultant Medtronic, Abbott, Spectranetics, speaker Medtronic, Spectranetics, Abbott, Convatec.

**Authorship**
All authors attest they meet the current ICMJE criteria for authorship.

**Patient Consent**
All patients enrolled in the LIFE study provided written informed consent.

**Ethics Statement**
The research reported in this paper adhered to the guidelines set forth by the Declaration of Helsinki. The LIFE study received institutional review board (IRB) approval of the protocol and ethics at each study center. IRB approval of the current study was waived due to the use of retrospective and deidentified data.

**References**
1. Wilkoff BL, Richards M, Sharma A, et al. A device histogram-based simple predictor of mortality risk in ICD and CRT-D patients: The Heart Rate Score. Pacing Clin Electrophysiol 2017;40:333–343.
2. Olshansky B, Richards M, Sharma A, et al. Survival after rate-responsive programming in patients with cardiac resynchronization therapy-debrillator implants is associated with a novel parameter: The Heart Rate Score. Circ Arhythm Electrophysiol 2016;9:e003806.
3. Richards M, Olshansky B, Sharma AD, et al. Addition of minute ventilation to rate-response pacing improves heart rate score more than accelerometer alone. Heart Rhythm 2018;15:1730–1735.
4. Coman J, Freedman R, Koplan BA, et al; LIFE Study Results. A blended sensor restores chronotropic response more favorably than an accelerometer alone in pacemaker patients: the LIFE study results. Pacing Clin Electrophysiol 2008; 11:1422–1442.
5. Wilkoff BL, Miller RE. Exercise testing for chronotropic assessment. Cardiol Clin 1992;10:705–717.
6. Wilkoff BL, Covey J, Blackburn G. A mathematical model of the cardiac chronotropic response to exercise. J Electrophysiol 1989;3:176–180.
7. The Criteria Committee for the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, Ninth edition. Little Brown and Company; 1994. p. 253–255.
8. Brubaker PH, Kitzman DW. Chronotropic incompetence. Causes, consequences, and management. Circulation 2011;123:1010–1020.
9. Fox SM, Haskell WL. The exercise stress test: needs for standardization. In: Eliakim M, Neufeld HN, eds. Cardiology: Current Topics and Progress. New York: Academic Press; 1970. p. 149–154.
10. Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart rate revisited. J Appl Physiol 2001;91:153–156.
11. Kay GN. Quantitation of chronotropic response: comparison of methods for rate modulating permanent pacemakers. J Am Coll Cardiol 1992;20:1533–1541.
12. Gupta M, Bansal V, Chhabra SK. Abnormal heart rate recovery and chronotropic incompetence in exercise in chronic obstructive pulmonary disease. Chron Respir Dis 2013;10:117–126.
13. Rubenstein JJ, Schulman CL, Yurchak PM, DeSanctis RW. Clinical spectrum of the sick sinus syndrome. Circulation 1972;46:5–13.
14. Elledridge M. Chronotropic incompetence: the implications of heart rate response to exercise (compensatory parasympathetic hyperactivity?). Circulation 1996;93:1485–1487.
15. Lauer MS, Francis GS, Okin PM, Pushkow FJ, Snader CE, Marwick TH. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA 1999;281:524–529.
16. Hinkle LE, Carver ST, Flakau A. Slow heart rates and increased risk of cardiac death in middle-aged men. Arch Intern Med 1972;129:732–748.
17. Ellestad MH, Wan MK. Predictive implications of stress testing: follow-up of 2700 subjects after maximum treadmill stress testing. Circulation 1975; 51:363–369.

18. Lauer MS, Okin PM, Larson MG, Evans JC, Levy D. Impaired heart rate response to graded exercise: prognostic implications of chronotropic incompetence in the Framingham Heart Study. Circulation 1996;93:1520–1526.

19. Zweerink A, van der Lingen A-C, Handoko ML, van Rossum AC, Allart CP. Chronotropic incompetence in chronic heart failure. Circ Heart Fail 2018; 11:e004969.

20. Roche F, Pichot V, Da Costa A, et al. Chronotropic incompetence response to exercise in congestive heart failure, relationship with autonomic status. Clin Physiol 2001;21:335–342.

21. Khan ME, Pohtier CE, Lauer MS. Chronotropic incompetence as a predictor of death among patients with normal electrocardiograms taking beta blockers. Am J Cardiol 2005;96:1328–1333.

22. Lamas GA, Knight JD, Sweeney M, et al. Impact of rate-modulated pacing on quality of life and exercise capacity: evidence from the Advanced Elements of Pacing Randomized Controlled Trial (ADEPT). Heart Rhythm 2007; 4:1125–1132.

23. Sowton E. Haemodynamic studies in patients with artificial pacemakers. Brit Heart J 1964;26:737–746.

24. Gierula J, Paton MF, Lowry JE, et al. Rate-response programming tailored to the force-frequency relationship improves exercise tolerance in chronic heart failure. JACC Heart Fail 2018;6:107–113.